Skip to Content
Merck

SML1394

Olmesartan

≥98% (HPLC), Angiotensin II Type I receptor blocker, powder

Synonym(s):

4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, Olmesartan acid

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H26N6O3
CAS Number:
144689-24-7
Molecular Weight:
446.50
UNSPSC Code:
12352200
PubChem Substance ID:
329825842
NACRES:
NA.77
MDL number:
MFCD09749896

Product Name

Olmesartan, ≥98% (HPLC)

SMILES string

OC(C)(C)C1=C(C(O)=O)N(CC2=CC=C(C3=C(C4=NNN=N4)C=CC=C3)C=C2)C(CCC)=N1

InChI

1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)

InChI key

VTRAEEWXHOVJFV-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... AGTR1(185)

Related Categories

Application

Olmesartan has been used as an angiotensin II receptor 1 (AT1) receptor inhibitor to study the effect of angiotensin II type 1 receptor interactions in the regulation of renal afferent arterioles in angiotensin II-dependent hypertension.

Biochem/physiol Actions

Olmesartan is an Angiotensin II Type I receptor blocker.
Olmesartan is an Angiotensin II Type I receptor blocker. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil.
Olmesartan possesses anti-inflammatory and anti-oxidative stress properties. It protects neuronal cells against oligomerized amyloid β (Aβ)-induced cellular senescence.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000390400
0000381193
0000381193
0000390400
0000249586

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ferrán Catalá-López et al.
PLoS medicine, 13(3), e1001971-e1001971 (2016-03-10)
Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of
Ariadne M Brondi et al.
Journal of analytical methods in chemistry, 2017, 4878316-4878316 (2018-02-03)
A study was carried out to investigate compatibility of amlodipine besylate and olmesartan medoxomil with a variety of pharmaceutical excipients. Both drugs are antihypertensive agents that can be administered alone, in monotherapy, or in pharmaceutical association. The studies were performed
Elham Bakhtiari et al.
Toxicology mechanisms and methods, 25(8), 614-621 (2015-09-04)
Over expression of renin-angiotensin system (RAS) and nuclear factor-kappaB (NF-κB) has a major role in many cancers. It has been suggested that some angiotensin receptor blockers (ARBs) could reduce the proliferation of cancer cells. The role of NF-κB pathway has
Nanako Muraya et al.
Oxidative medicine and cellular longevity, 2018, 7635274-7635274 (2018-07-04)
Oxidative stress induced by hyperuricemia is closely associated with the renin-angiotensin system, as well as the onset and progression of cardiovascular disease (CVD) and chronic kidney disease (CKD). It is therefore important to reduce oxidative stress to treat hyperuricemia. We
C Custodero et al.
Ageing research reviews, 46, 42-59 (2018-05-29)
Growing evidence suggests chronic low-grade inflammation (LGI) as a possible mechanism underlying the aging process. Some biological and pharmaceutical compounds may reduce systemic inflammation and potentially avert functional decline occurring with aging. The aim of the present meta-analysis was to
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service